Frederick L Baehner
Overview
Explore the profile of Frederick L Baehner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
9052
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Diergaarde B, Young G, Hall D, Mazloom A, Costa G, Subramaniam S, et al.
J Surg Oncol
. 2025 Jan;
PMID: 39865324
Background And Objectives: Identification of colorectal cancer (CRC) patients at high risk of recurrence could be of substantial clinical use. We evaluated the association of ctDNA status, using a tumor-informed...
2.
Karlsson P, Fyles A, Chang S, Arrick B, Baehner F, Malmstrom P, et al.
J Natl Cancer Inst
. 2024 Oct;
117(3):486-495.
PMID: 39423142
Background: There are currently no molecular tests to identify individual breast cancers where radiotherapy (RT) offers no benefit. Profile for the Omission of Local Adjuvant Radiotherapy (POLAR) is a 16-gene...
3.
Sparano J, Crager M, Gray R, Tang G, Hoag J, Baehner F, et al.
NEJM Evid
. 2024 Jul;
3(8):EVIDoa2300267.
PMID: 39041867
Background: The 21-gene recurrence score (RS) assay (Oncotype DX) is used to guide adjuvant chemotherapy use for patients with hormone receptor-positive, HER2 (human epidermal growth factor receptor 2)-negative, axillary node-negative...
4.
Association of Genomic Prostate Score at positive margin with recurrence after radical prostatectomy
Nourmohammadi Abadchi S, Salles D, Flannery C, Sama V, Baehner F, Zambon J, et al.
BJU Int
. 2024 Jul;
134(6):939-944.
PMID: 38953550
Objectives: To evaluate the utility of the 17-gene Genomic Prostate Score® (GPS; MDxHealth, Irvine, CA, USA) performed on prostate cancer at the positive margin of the radical prostatectomy (RP) for...
5.
McKelvey B, Andrews H, Baehner F, Chen J, Espenschied C, Fabrizio D, et al.
Diagnostics (Basel)
. 2024 May;
14(9).
PMID: 38732326
Circulating tumor DNA (ctDNA) holds promise as a biomarker for predicting clinical responses to therapy in solid tumors, and multiple ctDNA assays are in development. However, the heterogeneity in ctDNA...
6.
Yerushalmi R, Pomerantz A, Lewin R, Paluch-Shimon S, Soussan-Gutman L, Baehner F, et al.
Breast Cancer Res Treat
. 2024 Apr;
206(1):67-76.
PMID: 38568368
Purpose: We compared 21-gene recurrence score (RS) distribution and expression of the single-gene/gene groups within this assay between BC patients with pathogenic variants (PV) in BRCA1/2 vs the general 21-gene-tested...
7.
Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al.
J Clin Oncol
. 2023 Jul;
41(20):3565-3575.
PMID: 37406456
Purpose: The 21-gene recurrence score (RS) assay quantifies the likelihood of distant recurrence in women with estrogen receptor-positive, lymph node-negative breast cancer treated with adjuvant tamoxifen. The relationship between the...
8.
Chehrazi-Raffle A, Muddasani R, Dizman N, Hsu J, Meza L, Zengin Z, et al.
JCO Precis Oncol
. 2023 Apr;
7:e2200543.
PMID: 37027813
Purpose: Circulating tumor DNA (ctDNA) has been validated across multiple indications in the adjuvant and surveillance settings. We evaluated whether targeted digital sequencing (TARDIS) may distinguish a partial response (PR)...
9.
Crager M, Wijayawardana S, Gruver A, Blacklock A, Russell C, Baehner F, et al.
Breast Cancer Res
. 2022 Nov;
24(1):74.
PMID: 36320066
Background: The United States Food and Drug Administration recently approved a Ki-67 immunohistochemistry (IHC) assay to identify patients with early breast cancer at high disease recurrence risk. The Oncotype Dx...
10.
Yothers G, Venook A, Oki E, Niedzwiecki D, Lin Y, Crager M, et al.
J Gastrointest Oncol
. 2022 Mar;
13(1):126-136.
PMID: 35284101
Background: Individualized estimates of the risk of recurrence in colon cancer patients are needed that reflect current medical practice and available treatment options. Methods: Three validation studies of the 12-gene...